Obesity Treatment Market Research Report – Forecast to 2023

Global Obesity Treatment Market Research Report, by Type (Inactivity, Obesity gluten, Obesity), Diagnosis (Blood Tests, Physical Examination), Treatment (Medication, Surgery, Lifestyle Changes), End-Users (Hospitals, Clinics) - Global Forecast Till 2023

ID: MRFR/Pharma/4416-HCR | February 2021 | Region: Global | 100 pages

Market Scenario


Obesity is a disorder characterized by an excessive amount of body fat. The medical condition not only generates cosmetic concerns but is also related to various diseases and health problems, including heart diseases, diabetes, and others. A variety of treatment options are available in the market for obesity treatment, which ranges from medications to surgeries. Growing obese population and increasing acceptance of bariatric surgeries are expected to be the major drivers for the market growth during the forecast period. The Monash University stated that Australia recorded a burgeoning number of bariatric surgeries in 2015, accounting for approximately 15,000 procedures within the region. Moreover, the increasing demand for minimally invasive surgeries, rising awareness, and favorable reimbursement policies are expected to boost the market growth during the forecast period. However, factors such as high cost of surgery followed by the risks of infection and anesthesia allergy and low healthcare expenditure in the middle and low-income countries are estimated to restrain the market growth during the forecast period. According to a study published in the Obesity Surgery Journal in 2017, the mean total cost for bariatric procedures such as gastric bypass or adjustable gastric banding was estimated to be around USD 14,389.


The Global Obesity Treatment Market is expected to grow at an approximate CAGR of 16.7% during forecast period.
Figure 1- Global Obesity Treatment Market Share, by Region


 Obesity Treatment Market


Sources: Obesity Surgery journal, Eurostat, Monash University annual reports, press release, white paper, and company presentation


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Segmentation


The global obesity treatment market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the market is segmented into inactivity obesity, food obesity, anxiety obesity, venous obesity, atherogenic obesity, and gluten obesity. On the basis of diagnosis, the market is categorized into blood tests, physical examination, and others. The blood tests segment is sub-segmented into cholesterol test, liver function test, thyroid test, and others. The physical examination segment is sub-segmented into heart rate measurement, blood pressure measurement, and others. On the basis of treatment, the market is segmented into medication, surgery, lifestyle changes, and others. The medication segment is sub-segmented into orlistat, lorcaserin, phentermine and topiramate, liraglutide, and others. The surgery segment is sub-segmented into gastric bypass surgery, Laparoscopic Adjustable Gastric Banding (LAGB), gastric sleeve, biliopancreatic diversion, gastric sleeve, and others. On the basis of end-user, the market is segmented into hospitals, clinics, pharmacies, and others.


Key players


Some of the key players for the global obesity treatment market are VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), and others.


Research Methodology


 Methodology


Sources: Obesity Surgery journal, Eurostat, Monash University annual reports, press release, white paper, and company presentation


Regional Analysis


The Americas dominates the global market for obesity treatment due to an increasing obese population and presence of a well-developed healthcare sector. Moreover, factors such as changing lifestyle, the presence of developed economies, and increasing healthcare expenditure boost the market within the Americas.


Europe follows the Americas and stands second in the global obesity treatment market. The availability of funds for research, growing obese population, and increasing adoption of bariatric surgeries within the region are estimated to drive the market within the region. As per the Eurostat in 2016, more than half of the adults, accounting for 51.6% of the total population living within the European Union were estimated to be overweight. On a regional basis, Europe is divided into Western Europe and Eastern Europe. Western Europe leads the market in developed economies such as Italy, the U.K., France, and others.


Asia Pacific is estimated to be the fastest growing region and provides huge opportunities for the market growth. This can be attributed to the increasing obese population, continuously developing economies, and a growing healthcare sector within the region.  From 2014–2015, the Australian Institute of Health and Welfare stated that approximately two-thirds, i.e., 63% of the Australian population, aged 18 or more, were estimated to be overweight or obese.


On the other hand, the Middle East and Africa holds the least share in the global obesity treatment market due to the presence of poor economies and stringent government policies, especially within the Africa region. A majority of the market of the Middle East and Africa is estimated to be held by the Middle East.


 



Frequently Asked Questions (FAQ) :


On the basis of treatment, the Obesity Treatment Market is segmented into medication, surgery, lifestyle changes, and others.

The Obesity Treatment Market is expected to exhibit a strong 16.7% CAGR over the forecast period till 2023.

The growing prevalence of obesity is the major driver for the market.

North America is the leading regional market for obesity treatment.

Leading players in the Obesity Treatment Market include Novo Nordisk, Arena Pharmaceuticals, and Allergan, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Obesity Treatment Market, by Type

6.1 Introduction

6.2 Inactivity Obesity

Market Estimates & Forecast, 2017–2023

6.3 Food Obesity

Market Estimates & Forecast, 2017–2023

6.4 Anxiety Obesity

Market Estimates & Forecast, 2017–2023

6.5 Venous Obesity

Market Estimates & Forecast, 2017–2023

6.6 Atherogenic Obesity

Market Estimates & Forecast, 2017–2023

6.7 Gluten Obesity

Market Estimates & Forecast, 2017–2023
Chapter 7. Global Obesity Treatment Market, by Diagnosis

7.1 Introduction

7.2 Blood Tests

Market Estimates & Forecast, 2017–2023

7.2.1 Cholesterol Tests

7.2.2 Liver Function Tests

7.2.3 Thyroid Tests

7.3 Physical Examination

Market Estimates & Forecast, 2017–2023

7.3.1 Heart Rate Measurement

7.3.2 Blood Pressure Measurement

7.3.3 Others

7.4 Others

Chapter 8. Global Obesity Treatment Market, by Treatment

8.1 Introduction

8.2 Medication

Market Estimates & Forecast, 2017–2023

8.2.1 Orlistat

8.2.2 Lorcaserin

8.2.3 Phentermine and Topiramate

8.2.4 Liraglutide

8.2.5 Others

8.3 Surgery

Market Estimates & Forecast, 2017–2023

8.3.1 Gastric Bypass Surgery

8.3.2 Laparoscopic Adjustable Gastric Banding (LAGB)

8.3.3 Gastric Sleeve

8.3.4 Biliopancreatic Diversion

8.3.5 Gastric Sleeve

8.3.6 Others

8.4 Lifestyle Changes

8.5 Others

Chapter 9. Global Obesity Treatment Market, by End-User

9.1 Introduction

9.2 Hospitals

Market Estimates & Forecast, 2017–2023

9.3 Clinics

Market Estimates & Forecast, 2017–2023

9.4 Pharmacies

Market Estimates & Forecast, 2017–2023

9.5 Others

Chapter 10. Global Obesity Treatment Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 VIVUS, Inc.

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 Arena Pharmaceuticals, Inc.

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 F. Hoffmann-La Roche, Ltd.

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Novo Nordisk A/S

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Orexigen Therapeutics, Inc.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Allergan

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Cousin Biotech

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 EnteroMedics, Inc.

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Johnson & Johnson Services, Inc.

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Medtronic

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 USGI Medical, Inc.

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Mediflex Surgical Products

12.12.1 Overview

12.12.2 Type Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.13 Covidien plc

12.13.1 Overview

12.13.2 Type Overview

12.13.3 Financials

12.13.4 Key Developments

12.13.5 SWOT Analysis

12.14 Olympus Corporation

12.14.1 Overview

12.14.2 Type Overview

12.14.3 Financials

12.14.4 Key Developments

12.14.5 SWOT Analysis

12.15 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Global Obesity Treatment Market

Chapter 14 Appendix
LIST OF TABLES

Table 1 Obesity Treatment Industry Synopsis, 2017–2023

Table 2 Global Obesity Treatment Market Estimates & Forecast, 2017–2023, (USD Million)

Table 3 Global Obesity Treatment Market, by Region, 2017–2023, (USD Million)

Table 4 Global Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 5 Global Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 6 Global Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 7 Global Obesity Treatment Market, by End-User, 2017–2023, (USD Million

Table 8 North America Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 9 North America Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 10 North America Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 11 North America Obesity Treatment Market, by End-User, 2017–2023, (USD Million)

Table 12 U.S. Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 13 U.S. Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 14 U.S. Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 15 U.S. Obesity Treatment Market, by End-User, 2017–2023, (USD Million)

Table 16 Canada Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 17 Canada Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 18 Canada Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 19 Canada Obesity Treatment Market, by End-User, 2017–2023, (USD Million)

Table 20 South America Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 21 South America Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 22 South America Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 23 South America Obesity Treatment Market, by End-User, 2017–2023, (USD Million)

Table 24 Europe Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 25 Europe Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 26 Europe Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 27 Europe Obesity Treatment Market, by End-User, 2017–2023, (USD Million)

Table 28 Western Europe Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 29 Western Europe Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 30 Western Europe Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 31 Western Europe Obesity Treatment Market, by End-User, 2017–2023, (USD Million)

Table 32 Eastern Europe Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 33 Eastern Europe Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 34 Eastern Europe Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 35 Eastern Europe Obesity Treatment Market, by End-User, 2017–2023, (USD Million)

Table 36 Asia Pacific Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 37 Asia Pacific Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 38 Asia Pacific Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 39 Asia Pacific Obesity Treatment Market, by End-User, 2017–2023, (USD Million)

Table 40 The Middle East & Africa Obesity Treatment Market, by Type, 2017–2023, (USD Million)

Table 41 The Middle East & Africa Obesity Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 42 The Middle East & Africa Obesity Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 43 The Middle East & Africa Obesity Treatment Market, by End-User, 2017–2023, (USD Million)
LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Obesity Treatment Market

Figure 3 Market Dynamics for Global Obesity Treatment Market

Figure 4 Global Obesity Treatment Market Share, by Type 2016

Figure 5 Global Obesity Treatment Market Share, by Diagnosis 2016

Figure 6 Global Obesity Treatment Market Share, by Treatment, 2016

Figure 7 Global Obesity Treatment Market Share, by End-User, 2016

Figure 8 Global Obesity Treatment Market Share, by Region, 2016

Figure 9 North America Obesity Treatment Market Share, by Country, 2016

Figure 10 Europe Obesity Treatment Market Share, by Country, 2016

Figure 11 Asia Pacific Obesity Treatment Market Share, by Country, 2016

Figure 12 The Middle East & Africa Obesity Treatment Market Share, by Country, 2016

Figure 13 Global Obesity Treatment Market: Company Share Analysis, 2016 (%)

Figure 14 VIVUS, Inc.: Key Financials

Figure 15 VIVUS, Inc.: Segmental Revenue

Figure 16 VIVUS, Inc.: Geographical Revenue

Figure 17 Arena Pharmaceuticals, Inc.: Key Financials

Figure 18 Arena Pharmaceuticals, Inc.: Segmental Revenue

Figure 19 Arena Pharmaceuticals, Inc.: Geographical Revenue

Figure 20 F. Hoffmann-La Roche, Ltd.: Key Financials

Figure 21 F. Hoffmann-La Roche, Ltd.: Segmental Revenue

Figure 22 F. Hoffmann-La Roche, Ltd.: Geographical Revenue

Figure 23 Novo Nordisk A/S: Key Financials

Figure 24 Novo Nordisk A/S: Segmental Revenue

Figure 25 Novo Nordisk A/S: Geographical Revenue

Figure 26 Orexigen Therapeutics, Inc.: Key Financials

Figure 27 Orexigen Therapeutics, Inc.: Segmental Revenue

Figure 28 Orexigen Therapeutics, Inc.: Geographical Revenue

Figure 29 Allergan: Key Financials

Figure 30 Allergan: Segmental Revenue

Figure 31 Allergan: Geographical Revenue

Figure 32 Cousin Biotech: Key Financials

Figure 33 Cousin Biotech: Segmental Revenue

Figure 34 Cousin Biotech: Geographical Revenue

Figure 35 EnteroMedics, Inc.: Key Financials

Figure 36 EnteroMedics, Inc.: Segmental Revenue

Figure 37 EnteroMedics, Inc.: Geographical Revenue

Figure 38 Johnson & Johnson Services, Inc.: Key Financials

Figure 39 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 40 Johnson & Johnson Services, Inc.: Geographical Revenue

Figure 41 Medtronic: Key Financials

Figure 42 Medtronic: Segmental Revenue

Figure 43 Medtronic: Geographical Revenue

Figure 44 USGI Medical, Inc.: Key Financials

Figure 45 USGI Medical, Inc.: Segmental Revenue

Figure 46 USGI Medical, Inc.: Geographical Revenue

Figure 47 Mediflex Surgical Products: Key Financials

Figure 48 Mediflex Surgical Products: Segmental Revenue

Figure 49 Mediflex Surgical Products: Geographical Revenue

Figure 50 Covidien plc: Key Financials

Figure 51 Covidien plc: Segmental Revenue

Figure 52 Covidien plc: Geographical Revenue

Figure 53 Olympus Corporation: Key Financials

Figure 54 Olympus Corporation: Segmental Revenue

Figure 55 Olympus Corporation: Geographical Revenue